This study demonstrates that Wnt5a can induce Rac1 activation, which leads to enhanced proliferation of primary MCL cells via a ROR1-dependent signaling-pathway that can be blocked by cirmtuzumab. This evidence concerns the gene RAC1 and mantle cell lymphoma.